204 related articles for article (PubMed ID: 16857824)
1. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4436s-4440s. PubMed ID: 16857824
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Herbst RS; Davies AM; Natale RB; Dang TP; Schiller JH; Garland LL; Miller VA; Mendelson D; Van den Abbeele AD; Melenevsky Y; de Vries DJ; Eberhard DA; Lyons B; Lutzker SG; Johnson BE
Clin Cancer Res; 2007 Oct; 13(20):6175-81. PubMed ID: 17947484
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Gordon MS; Matei D; Aghajanian C; Matulonis UA; Brewer M; Fleming GF; Hainsworth JD; Garcia AA; Pegram MD; Schilder RJ; Cohn DE; Roman L; Derynck MK; Ng K; Lyons B; Allison DE; Eberhard DA; Pham TQ; Dere RC; Karlan BY
J Clin Oncol; 2006 Sep; 24(26):4324-32. PubMed ID: 16896006
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
5. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
6. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
Kristjansdottir K; Dizon D
Expert Opin Biol Ther; 2010 Feb; 10(2):243-50. PubMed ID: 20001562
[TBL] [Abstract][Full Text] [Related]
7. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
Yamamoto N; Yamada Y; Fujiwara Y; Yamada K; Fujisaka Y; Shimizu T; Tamura T
Jpn J Clin Oncol; 2009 Apr; 39(4):260-6. PubMed ID: 19261664
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab: development beyond breast cancer.
Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
[TBL] [Abstract][Full Text] [Related]
11. Her2-targeted therapies in non-small cell lung cancer.
Swanton C; Futreal A; Eisen T
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4377s-4383s. PubMed ID: 16857814
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Agus DB; Sweeney CJ; Morris MJ; Mendelson DS; McNeel DG; Ahmann FR; Wang J; Derynck MK; Ng K; Lyons B; Allison DE; Kattan MW; Scher HI
J Clin Oncol; 2007 Feb; 25(6):675-81. PubMed ID: 17308272
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab: optimizing HER2 blockade.
Metzger-Filho O; Winer EP; Krop I
Clin Cancer Res; 2013 Oct; 19(20):5552-6. PubMed ID: 23942091
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
Agus DB; Gordon MS; Taylor C; Natale RB; Karlan B; Mendelson DS; Press MF; Allison DE; Sliwkowski MX; Lieberman G; Kelsey SM; Fyfe G
J Clin Oncol; 2005 Apr; 23(11):2534-43. PubMed ID: 15699478
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Hughes B; Mileshkin L; Townley P; Gitlitz B; Eaton K; Mitchell P; Hicks R; Wood K; Amler L; Fine BM; Loecke D; Pirzkall A
Oncologist; 2014 Feb; 19(2):175-6. PubMed ID: 24457379
[TBL] [Abstract][Full Text] [Related]
17. [Pertuzumab and solid tumors: perspectives].
Barthélémy P; Leblanc J; Wendling F; Wissler MP; Bergerat JP
Bull Cancer; 2014 Dec; 101(12):1114-21. PubMed ID: 25532690
[TBL] [Abstract][Full Text] [Related]
18. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
Clamon G; Herndon J; Kern J; Govindan R; Garst J; Watson D; Green M;
Cancer; 2005 Apr; 103(8):1670-5. PubMed ID: 15751020
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
